Literature DB >> 33489582

Severe Post-Herpetic Lumbar Plexopathy Responds to Pulse Intravenous Methylprednisolone: A Case Report With a Side Note on its Parallel Semiology to Diabetic Radiculoplexopathy and the Vascular Invasiveness of the Varicella-Zoster Virus.

Hassan Kesserwani1.   

Abstract

Post-herpetic lumbar plexopathy (post-herpetic segmental paresis), immune-mediated lumbar plexopathy and diabetic radiculoplexopathy (diabetic amyotrophy) have similar and seemingly parallel semiologies. The latter two conditions have an underlying microvasculitic pathological substrate that has shown potential (yet unproven) amelioration with immunodulatory therapy. These observations gave us the motivation to treat our patient with intravenous methylprednisolone for a profound proximal left leg weakness due to post-herpetic segmental paresis. In this case report, we outline in detail the clinical and electophysiolgical phenotype of this disease and we demonstrate the spectacular improvement of left leg power that had previously remained static for three months. In the discussion section, we review the vascular invasiveness of the varicella-zoster virus.
Copyright © 2020, Kesserwani et al.

Entities:  

Keywords:  plexopathy; varicella-zoster

Year:  2020        PMID: 33489582      PMCID: PMC7813428          DOI: 10.7759/cureus.12171

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  19 in total

1.  Varicella zoster virus vasculopathy: analysis of virus-infected arteries.

Authors:  M A Nagel; I Traktinskiy; Y Azarkh; B Kleinschmidt-DeMasters; T Hedley-Whyte; A Russman; E M VanEgmond; K Stenmark; M Frid; R Mahalingam; M Wellish; A Choe; R Cordery-Cotter; R J Cohrs; D Gilden
Journal:  Neurology       Date:  2011-07-13       Impact factor: 9.910

2.  Diabetic amyotrophy in an adolescent responsive to intravenous immunoglobulin.

Authors:  Jose Americo Fernandes Filho; Brandon M Nathan; Mark R Palmert; Bashar Katirji
Journal:  Muscle Nerve       Date:  2005-12       Impact factor: 3.217

3.  A case of diabetic amyotrophy with severe atrophy and weakness of shoulder girdle muscles showing good response to intravenous immune globulin.

Authors:  Yuko Wada; Chie Yanagihara; Yo Nishimura; Nobuyuki Oka
Journal:  Diabetes Res Clin Pract       Date:  2006-06-16       Impact factor: 5.602

4.  Microvasculitis in non-diabetic lumbosacral radiculoplexus neuropathy (LSRPN): similarity to the diabetic variety (DLSRPN).

Authors:  P J Dyck; J Engelstad; J Norell; P J Dyck
Journal:  J Neuropathol Exp Neurol       Date:  2000-06       Impact factor: 3.685

5.  Varicella Zoster Virus Vasculopathy.

Authors:  Maria A Nagel; Andrew N Bubak
Journal:  J Infect Dis       Date:  2018-09-22       Impact factor: 5.226

6.  Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group.

Authors:  S Tyring; R A Barbarash; J E Nahlik; A Cunningham; J Marley; M Heng; T Jones; T Rea; R Boon; R Saltzman
Journal:  Ann Intern Med       Date:  1995-07-15       Impact factor: 25.391

7.  Segmental zoster paresis of limbs: report of three cases and review of literature.

Authors:  Sumihiro Kawajiri; Momo Tani; Kazuyuki Noda; Kenji Fujishima; Nobutaka Hattori; Yasuyuki Okuma
Journal:  Neurologist       Date:  2007-09       Impact factor: 1.398

Review 8.  Diabetic lumbosacral radiculoplexus neuropathy: a postmortem studied patient and review of the literature.

Authors:  David S Younger
Journal:  J Neurol       Date:  2011-02-17       Impact factor: 4.849

9.  A retrospective case series of segmental zoster paresis of limbs: clinical, electrophysiological and imaging characteristics.

Authors:  Ying Liu; Bing-Yun Wu; Zhen-Shen Ma; Juan-Juan Xu; Bing Yang; Heng Li; Rui-Sheng Duan
Journal:  BMC Neurol       Date:  2018-08-21       Impact factor: 2.474

10.  Update on varicella zoster virus vasculopathy.

Authors:  Maria A Nagel; Don Gilden
Journal:  Curr Infect Dis Rep       Date:  2014-06       Impact factor: 3.663

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.